Vamsi Pavan Kumar Allu’s Post

Tune into the latest Genetic Engineering & Biotechnology News podcast, “How Biotechs are Plugging AI into Drug Discovery Problems." This episode features Jonathan D. Grinstein, PhD, and Fay Lin, PhD discussing the essential role of #AI in drug development. They emphasize our focus on data and extrapolating meaningful insights from it. Additionally, they highlight our strategic investment in #CryoEM, which significantly enhances our predictive capabilities in protein functionality. Listen to the full episode for more insights on the transformative impact of AI in biotechnology. #GenerativeAI | #ProteinEngineering

How Is AI Transforming Large Molecule Drug Development? 🧬 Our next pharma interview is out now! This time, we invited Jelena Ivanovska, PhD, CSO at Exazyme, Dr. Harry Sevi, ML Engineer at Exazyme, and Dr. Gillian Lee Hertlein, Strategic Project Manager at Merantix Momentum, to explore AI-driven compound optimization in the large molecule space. Key Insights Include: ▶ The role of large molecules like proteins in therapeutics and the optimization goals for macromolecules. ▶ AlphaFold's breakthrough in accurately predicting protein structures, revolutionizing drug development. ▶ The potential and challenges of AI-based modeling for improving predictions of protein functionality. ▶ The future of generative AI in designing proteins and antibodies and what's on the horizon. 👉 Read the full interview here: https://lnkd.in/eEiyQj7S #artificialintelligence #machinelearning #pharma #drugdevelopment

Nature's blueprints: advancing drug development with biomimetic culture Explore: The art of creating models that bridge the gap between in vitro and in vivo, enhancing biological relevance. Practical considerations of crafting and sustaining these cultures. The impact of biomimetic culture on disease modeling, drug development, and preclinical evaluation. Click below to access.

"Drug development teams have found significant data and modeling challenges in regard to tackling the complexities associated with #PDIinhibitors given the challenges with creating meaningful models, and accumulating and deciphering the data," said Panna Sharma, CEO and President of Lantern Pharma. "Our #AI platform, RADR®, can increase the confidence, insights, and comfort levels in developing data-driven development paths by modeling highly complex scenarios at a scale that only has become possible recently. It’s an ideal approach for Oregon Therapeutics, which has executed a series of highly targeted in vivo and in vitro experiments and is poised to make incredibly important and patient-centric decisions about the clinical future of the molecule. That's where RADR® can play a highly essential and market defining role." https://lnkd.in/g8XPQSsa #biotech #businessdevelopment #artificialintelligence

We’re excited to announce our collaboration with Bristol Myers Squibb applying Menten AI’s generative AI platform to peptide optimization. By leveraging Menten AI’s generative AI platform and the team’s expertise, we were able to explore a more expansive chemical space and identify new amino acid modifications to improve the desired properties of peptide macrocycles. It’s been a pleasure working with the world-class scientists at Bristol Myers Squibb. Thank you for the incredible collaboration! This is a key milestone for Menten AI, as it demonstrates the maturity of our platform and of generative AI more broadly, to accelerate the discovery and optimization of next-generation peptide macrocycles. Learn more about this collaboration: https://lnkd.in/dcW-8bdq #aidrugdiscovery #genai #biotech #drugdiscovery #peptides #hitdiscovery #drugdiscovery #drugdevelopment #peptides #peptidetherapy #cyclicpeptides #macrocycles  #artificialintelligence #ai #generativeai #therapeutics  #aminoacids #chemicalspace #mentenai #partnering #biotechnology #innovation #machinelearning #ml

In a recent interview, Jane King and Professor Ari Zoldan spoke with Jennifer Bath, Ph.D., CEO of IPA (ImmunoPrecise Antibodies), about their pioneering 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐛𝐢𝐨𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬. Dr. Bath elaborates on how IPA’s proprietary Lens AI software is streamlining drug discovery, manufacturing, and patient trials, positioning 𝐈𝐏𝐀 𝐚𝐬 𝐚 𝐥𝐞𝐚𝐝𝐞𝐫 𝐢𝐧 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲. Watch the full interview to learn more about IPA Therapeutics and their groundbreaking technology: https://lnkd.in/eVJZAy_T #ArtificialIntelligence #LensAI #Biotherapeutics #IPATherapeutics

AI-First Drug Design: Accelerating the Discovery of New Therapeutics | https://lnkd.in/gDJRSdz7 Thu, Dec 12, 2024 8 AM PST / 11 AM EST / 5 PM CEST There is growing interest around the application of artificial intelligence in drug design and discovery. Advanced computational and AI-driven methods have the potential to transform the field by accelerating, augmenting and enhancing drug design, the development process and clinical trials. Curious to see how those at the forefront of AI see its potential impact in drug discovery? In this Flash Talk, Rebecca Paul, Head of Medicinal Drug Design at Isomorphic Labs, will share her insights on how AlphaFold 3 is applied along with other breakthrough AI models to advance the rational design and optimization of small molecules. Register here: https://lnkd.in/gh7ecSZi

Here is a landscape of AI-discovered molecules and also target novelty analysis. With BioPharmaTrend.com, we have recently launched a report, “It’s Been a Decade of AI in the Drug Discovery Race. What’s Next?” where we gathered historical data about drug pipeline progression over the years for the select AI-driven drug discovery platforms (link to the free report is in the comments). Those included BenevolentAI, Exscientia, insitro, Insilico Medicine, Recursion, Relay Therapeutics, Schrödinger, Verge Genomics, and Valo Health. Now, we’ve gone a step further and attempted to analyze novelties of targets that the above companies are pursuing for their leading drug programs. Some of the targets were really novel and even AI-discovered, like in the case of Insilico Medicine, Recursion Pharmaceuticals, Schrodinger and Verge Genomics. In other cases, targets were moderately novel, or even very old and well-known. The diagram below is a small part of our ongoing study into AI productivity in drug discovery, and I welcome your thoughts on this in the comments. First insights from the next study iterations will be available via our Substack newsletter, “Where Tech Meets Bio,” (link in the comments) Please subscribe there to get early insights. #drugdiscovery #techbio #biopharmatrend #artificialintelligence Image credit: BiopharmaTrend

WOW! Have you seen this chart? This may be the first attempt to assess target novelty by any biotech. We do this for living with PandaOmics and for big pharma companies. And while I disagree with the many assessments in the report and won't be able to use it (e.g. PHD1/2 is not new but the indication for a Gut-restricted molecule makes it moderately novel), this is truly industry's first. In the age of generative AI, assessing novelty will be a whole new job by itself. Happy to see that BioPharmaTrend.com is doing this - we have been preaching the need for novelty assessment for a long time. It is needed more for government, journal editors, and grant makers, but may be interesting to scientists - I want to work in moderately-novel targets where I know that if I do well in preclinical, I can out-license the program early instead of waiting for Phase 2 data POC.